| |
|
|
|
|
|
||||
|
|
|
|
|
|||||||||||||||
|
HIV Development Activities
Integrase inhibitors represent a new class of anti-HIV medicines that target the enzyme integrase. Integrase is one of three enzymes necessary for viral replication. This enzyme assists in the integration of viral DNA into the DNA of the host cell. It is the only enzyme unaffected by currently available anti-HIV medicines. Researchers at Shionogi Research Laboratories have discovered several compounds that have demonstrated potent inhibition of the integrase enzyme. New lead candidates are currently being developed jointly within Shionogi-GlaxoSmithKline Pharmaceuticals. "Progressing research on integrase inhibitors is an important step forward for AIDS research. Like reverse transcriptase and protease, integrase is essential for the virus to infect cells and replicate. Inhibiting integrase could be a new way to suppress the virus and extend treatment options for patients, especially those with resistance to currently available anti-HIV drugs" said Dr. Tamio Fujiwara, General Manager, Antiviral Research Program, Shionogi Institute for Medical Science. Compounds marked by * are being developed through Shionogi-GlaxoSmithKline
Pharmaceuticals, LLC, a joint venture that Shionogi USA supports. Related Press Releases
|
||||||||||||||||
|
|
|||||||||||||||
